Antibody Drug and Target Discovery for Cancer Therapies

Guest Editor:

Dr. Nicolas Bery
Centre de Recherches en Cancérologie de Toulouse (CRCT), U1037 INSERM, Université Toulouse III, U5071 CNRS, 31100 Toulouse, France

Deadline for manuscript submissions:
closed (20 October 2022)

Message from the Guest Editor

Antibodies are a class of biological therapeutics that is quickly expanding with now more than 100 antibodies approved by the FDA. All of these drugs bind extracellular or transmembrane targets and most of them inhibit their target function by blocking receptor-ligand interactions. However, therapeutic antibodies are not limited to canonical antibodies and other avenues such as antibody-drug conjugate (ADC) or bispecific antibodies in oncoimmunology are exciting possibilities for cancer therapies. In the future, intracellular antibodies—i.e., expressed within the cells—may have a huge impact on cancer treatments once their delivery will be efficient for inhibiting intracellular targets in clinic.

This Special Issue of Antibodies aims to provide an up-to-date overview of therapeutic antibodies but also of the use of antibodies (or fragment antibodies) for discovering novel therapeutic targets of interest (either extra or intracellular ones) or novel inhibitory mechanisms and their validation. In this Special Issue, original research articles and reviews are welcome and should cover the aforementioned topics applied to cancer therapies.

mdpi.com/si/100426

Special Issue

Editor-in-Chief

Prof. Dr. Arne Skerra
Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: CiteScore - Q1 (*Drug Discovery*)

Contact Us